Conatus Pharmaceuticals (NASDAQ:CNAT) – Investment analysts at SunTrust Banks issued their Q1 2018 EPS estimates for shares of Conatus Pharmaceuticals in a research note issued on Thursday, according to Zacks Investment Research. SunTrust Banks analyst J. Boris forecasts that the biotechnology company will earn ($0.22) per share for the quarter. SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.26) EPS, FY2021 earnings at $2.44 EPS and FY2022 earnings at $6.69 EPS.
Other equities research analysts also recently issued research reports about the stock. S&P Equity Research increased their target price on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a research report on Wednesday, January 24th. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a report on Thursday, February 8th. They set a “buy” rating and a $20.00 price target on the stock. Oppenheimer restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Thursday, March 22nd. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Conatus Pharmaceuticals in a report on Thursday, March 8th. Finally, Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Conatus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $13.67.
CNAT stock traded down $0.31 during midday trading on Friday, reaching $5.56. The company had a trading volume of 410,687 shares, compared to its average volume of 597,723. Conatus Pharmaceuticals has a 1 year low of $3.88 and a 1 year high of $9.40. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.47. The company has a market cap of $176.45, a price-to-earnings ratio of -9.11 and a beta of 1.16.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%. The company had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.60 million.
Several institutional investors have recently added to or reduced their stakes in the company. MPM Asset Management LLC raised its holdings in shares of Conatus Pharmaceuticals by 76.3% during the 4th quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock valued at $9,707,000 after purchasing an additional 909,091 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Conatus Pharmaceuticals by 6.2% during the 4th quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock valued at $7,362,000 after purchasing an additional 93,015 shares in the last quarter. Vanguard Group Inc. grew its stake in Conatus Pharmaceuticals by 31.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after buying an additional 239,373 shares during the last quarter. Geode Capital Management LLC grew its stake in Conatus Pharmaceuticals by 26.2% in the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock valued at $1,983,000 after buying an additional 89,179 shares during the last quarter. Finally, State Street Corp acquired a new position in Conatus Pharmaceuticals in the 2nd quarter valued at $2,092,000. Institutional investors and hedge funds own 39.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Conatus Pharmaceuticals to Post Q1 2018 Earnings of ($0.22) Per Share, SunTrust Banks Forecasts (NASDAQ:CNAT)” was first posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://theenterpriseleader.com/2018/04/02/research-analysts-issue-forecasts-for-conatus-pharmaceuticals-incs-q1-2018-earnings-nasdaqcnat.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.